IMC-001
Phase 2Small molecule
IMC-001 is one of 85 small molecule programs targeting Lymphoma. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Tafasitamab
IncytePreclinical
IMC-001
IImmuneOncia Therapeutics Inc.
Phase 2
Nuvigil
NNuvo Research GmbH
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced1 trial
Intestinal Cancer1 trial
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
Active, not recruiting·—·Phase 2·NCT04196465·48 enrolled
Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMC-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmuneOncia Therapeutics Inc.